Avalun
Avalun is a French medical device company developing the Labpad, a point-of-care in vitro diagnostic platform that delivers rapid biological test results from small sample volumes for clinical and decentralized testing applications.
- Company typePublic
- Founded2005
- HeadquartersGrenoble, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Avalun does
Avalun is a privately-held French medical device company founded in 2013 and headquartered in Grenoble, within the broader Grenoble-Alpes life sciences and microelectronics cluster. The company develops the Labpad, an in vitro diagnostic (IVD) platform that delivers rapid biological test results from small sample volumes, targeting use cases where conventional centralized laboratory processing is impractical or too slow. The Labpad is described as a compact device enabling quantitative biological measurements from capillary or finger-prick samples, positioning Avalun in the point-of-care and decentralized testing segment of the IVD market.
The product architecture is built around a microfluidic cartridge-based reader, with consumable cartridges and the instrument forming the core of the offering. The platform is designed to support clinical, pharmaceutical, and consumer health applications where miniaturized hardware and small sample volumes are valued. The company operates with 11-50 employees, indicating a small organization likely still in development or early commercial stages rather than a scaled manufacturer.
No revenue, funding rounds, pricing model, customer logos, or channel information was disclosed in the input corpus for Avalun, and the business model (instruments, consumables, licensing, or a mix) cannot be characterized from the available data. The source corpus additionally contains detailed records for Biosynex SA, a separate French rapid diagnostic test distributor founded in 2005, but no explicit corporate or commercial link between Avalun and Biosynex is documented in the provided data, and Biosynex information has not been used to characterize Avalun.
Avalun firmographics
Firmographics- Name
- Avalun
- Legal name
- Biosynex SA
- Website
- https://avalun.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Avalun is a French medical device company developing the Labpad, a point-of-care in vitro diagnostic platform that delivers rapid biological test results from small sample volumes for clinical and decentralized testing applications.
- Ownership category
- akta.pro rank
Where Avalun is headquartered
LocationHeadquarters
- HQ city
- Grenoble
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Avalun business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Rapid Diagnostic Tests Distribution: Design, manufacture and distribution of rapid diagnostic tests to healthcare networks including laboratories, hospitals, pharmacies, and retail stores
- Point of Care Devices: Sale of specialized diagnostic instruments and readers for medical professionals
- Molecular Biology Products: Distribution of molecular biology testing solutions and reagents
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
Avalun product offering
Product offeringCore offering
Avalun develops and commercializes the Labpad, an in vitro diagnostic device that delivers rapid biological test results from small sample volumes. The device is designed for point-of-care clinical use, enabling healthcare professionals to obtain biological test outcomes quickly without requiring large sample volumes or centralized laboratory processing.
Product overview
No source data available for Avalun. The provided source material contains information about Biosynex, a French company specializing in the design and distribution of rapid diagnostic tests, not Avalun.
Differentiator
Problem solved
Functional benefit
Brands
- Biosynex Pharma: Pharmacy division of the Biosynex Group
- Ampliflash
- Ampliquick
- Vita PCR
- Skyla HB1
- Procise DX
- Pathfast
- BSX Reader
- Parakito
- Bodyflash
Products and services
- Labpad The Labpad is an in vitro diagnostic device developed by Avalun that delivers rapid biological test results from small sample volumes. It is designed for clinical and point-of-care use by healthcare professionals, laboratories, and hospitals needing fast biological testing at the point of need.
Companies that use Avalun
Customer profileSegments4 records
Ideal customer profiles1 record
Avalun technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Avalun partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- THERADIAGcoreBiosynex announced a merger by absorption project with THERADIAG, a company specializing in the design, distribution and commercialization of in vitro diagnostic devices. This strategic merger aims to strengthen Biosynex's position in the diagnostic market.
- PROCISEDXcoreBiosynex took control and acquired 100% of PROCISEDX capital on June 9, 2023. ProciseDx develops and commercializes diagnostic systems. FDA authorization received for infliximab dosage tests.
- INNOXAminorAcquisition of the eye care (soins oculaires) activity from INNOXA laboratories. This acquisition strengthens the Pharmacy Division of the BIOSYNEX Group (BIOSYNEX Pharma) with a range of eye care and prevention products.
- CHEMBIO DIAGNOSTICS Inc.coreCompleted acquisition of CHEMBIO DIAGNOSTICS Inc. through an OPA (tender offer). This acquisition represents a major milestone in BIOSYNEX's history, integrating the company into the Biosynex Group.
- CredoDiagnostics Biomedical Pte LtdminorExtension of the distribution agreement between Credo Diagnostics and Biosynex with an exclusivity agreement for an extended territory including the United Kingdom. The partnership was strengthened following the acquisition of BHR.
Scale indicators2 records
Avalun competitors and assessment
Company assessmentDirect peers
- Biosynex: French rapid diagnostic test designer and distributor serving laboratories, hospitals, and pharmacies across 90+ countries. Comparable as a similarly positioned French IVD player addressing rapid decentralized testing through both rapid tests and point-of-care readers, and geographically proximate to Avalun.
- Response Biomedical: Canadian IVD company developing rapid diagnostic tests and the RAMP point-of-care immunoassay reader platform. Comparable as a similarly sized, product-focused developer of compact readers delivering rapid quantitative results.
Broad incumbents
- bioMérieux: Global French IVD leader with a broad portfolio spanning microbiology, molecular diagnostics, and industrial applications. Overlaps with Avalun in IVD instrumentation and clinical diagnostics but operates at substantially greater scale and product breadth.
- Cepheid (Danaher): Molecular diagnostics platform behind the GeneXpert system, delivering rapid PCR-based results at the point of care. Comparable as a connected diagnostic instrument platform targeting decentralized testing workflows in clinical settings.
- Abbott Point of Care: Global IVD leader with the i-STAT handheld clinical chemistry and immunoassay systems. Direct competition in the handheld, rapid-results diagnostic instrument category with a far larger commercial and installed-base footprint than Avalun.
- QuidelOrtho: Specialized IVD company built around rapid immunoassays, clinical chemistry, and molecular diagnostics. Comparable as a developer of rapid-result diagnostic devices and assays for decentralized and reference-lab settings.
- Meridian Bioscience: IVD developer and manufacturer of diagnostic tests, reagents, and sample preparation kits serving clinical and reference laboratories. Comparable in offering integrated test-and-instrument solutions across clinical diagnostic use cases.
Emerging players
- Trinity Biotech: Specialized IVD developer focused on point-of-care and clinical laboratory diagnostics, including hemoglobin A1c testing and infectious disease screening. Comparable in mission and target use cases for decentralized testing, though somewhat larger in scale.
- Erba Mannheim: IVD developer with a portfolio of clinical chemistry, hematology, immunoassay, and point-of-care systems. Comparable as a mid-sized developer of compact diagnostic instruments targeting decentralized and small-lab markets.
- Quotient Limited: Specialized diagnostics developer of the MosaiQ transfusion diagnostics platform. Comparable as a smaller developer of compact, integrated diagnostic instruments for decentralized clinical workflows.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat1 record
Key risks3 records
Key highlights4 records
Customer concentration
Avalun social profiles
Digital presenceAvalun financial estimates
Financial estimateRevenue estimate
Valuation estimate
Avalun leadership team
Management profileNumber of profiles
Avalun subsidiaries and ownership
Company hierarchySubsidiaries4 records
Avalun funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Avalun M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Avalun
What does Avalun do?
Avalun develops and commercializes the Labpad, an in vitro diagnostic device that delivers rapid biological test results from small sample volumes. The device is designed for point-of-care clinical use, enabling healthcare professionals to obtain biological test outcomes quickly without requiring large sample volumes or centralized laboratory processing.
Is Avalun a public or private company?
Avalun is a public company. It is classified as unknown and is currently operating.
When was Avalun founded?
Avalun was founded in 2005. It employs 11 to 50 people.
Where is Avalun based?
Avalun is headquartered in Grenoble, France, in the Europe region.
How does Avalun make money?
Three revenue lines are on record. Rapid Diagnostic Tests Distribution is the primary driver. The others are point of Care Devices and molecular Biology Products.
Who are Avalun's main competitors?
Direct peers on record are Biosynex and Response Biomedical. Broad incumbents are bioMérieux, Cepheid (Danaher), Abbott Point of Care, QuidelOrtho and Meridian Bioscience. Emerging players are Trinity Biotech, Erba Mannheim and Quotient Limited.
Does Avalun have an API?
No public API is recorded for Avalun.